Introduction {#sec1}
============

As a subset of systems biology, systems toxicology aims to describe the resilience of biological systems to perturbation by toxicants, i.e., the ability (or lack thereof) to return to normal function. The toxicological community in the 21st century is repositioning from empirical, animal-based testing to a mechanistic understanding of chemical-induced biological perturbation in toxicity pathways and networks,^[@ref1]^ ushering in a radical rethinking of safety assessment.

This repositioning has been driven by the revolution in genomics and a systems-oriented perspective on biology that aims to address biological processes as integrated systems of diverse interacting components.^[@ref2]^ An understanding of biology from a systems perspective involves^[@ref3]^ (1) collection of large sets of experimental data by high-content technologies and/or by mining molecular biology and biochemistry literature and databases; (2) proposal of mathematical models that might account for at least some significant aspects of this data set; (3) accurate computer simulation of the mathematical models to obtain numerical predictions; and (4) assessment of the quality of the models by comparing numerical simulations with the experimental data.

Systems Toxicology adds to this challenge a requirement to describe the perturbation of these systems and their resilience,^[@ref4]^ in response to potential hazardous exposures. An overarching goal of Systems Toxicology is to relate complex exposures, via susceptibility factors and alterations of biological processes with impacts on a population level. A practical building block involves reliable experimental model systems to measure key events along pathways, which are really networks, and linking them to adverse outcomes. Addressing such adverse outcome pathways from a network perspective involves diverse strategies for the integrative analysis of omics measurements. Finally, observed network perturbations and the mathematical models that describe them need to be linked with particular phenotypes. This requires computational and empirical approaches for prediction and qualification.

Building on a highly successful Systems Toxicology conference held in Ascona, Switzerland in 2013, a second Systems Toxicology meeting was held in Les Diablerets, Switzerland, in early 2016.^[@ref5]^ The 2013 meeting set out to evaluate how state-of-the-art systems biology tools can be used to elucidate toxicity pathways and provide realistic exposure and outcome assessments, as well as to establish a general framework for interpreting and applying Systems Toxicology data to inform chemical risk assessment policy and regulation.^[@ref1]^ Three years later, the aim was to explore in greater detail specific applications of systems toxicology approaches. The objectives of the conference were to (1) illustrate real-world examples of how systems toxicology could be applied to elucidate toxic modes of action and contribute to realistic exposure and biological impact assessments; (2) learn how experimental and computational elements could be integrated in systems toxicology-based approaches; (3) reveal recent advances in complementary and multidisciplinary research with the potential to enhance further development and application of systems toxicology; and (4) bridge scientific approaches in systems toxicology with applications in human toxicological risk assessment.

This perspective is based on presentations and discussions at the 2016 Systems Toxicology meeting. It is a simple and incomplete but we hope useful snapshot of current aspects of this rapidly developing field. The perspective addresses first the type of pathway information required for Systems Toxicology and the requirements the model systems and omics measurements have to satisfy to derive such information. Furthermore, it addresses three key challenges, i.e., how to link network perturbations to phenotypes, how to address uncertainty in computational models, and how to develop pathway-based testing strategies as a step toward systems toxicology risk assessment. Finally, a number of emerging examples toward systems toxicology are given, many of them recently highlighted in a *Chemical Research in Toxicology* virtual special issue on *Pathway-Based Approaches for Environmental Monitoring and Risk Assessment*.^[@ref6]^

Toxicity Pathways and Networks {#sec2}
==============================

Pathway-based toxicology is at the core of the 21st Century Toxicity Testing vision (NRC 2007).^[@ref7]^ Pathway-based mechanistic analysis is particularly important in interpreting the growing amount of chemical toxicity data based on high-content^[@ref8],[@ref9]^ and high-throughput screening (HTS).^[@ref10]^ For instance, how does one interpret the impact of toxicants on hundreds of proteins and genes in multiple pathways? What does it mean if multiple toxicants have shared mechanisms and pathways? Many toxicants actually simultaneously activate multiple pathways; this phenomenon has been termed *promiscuity* in chemical toxicity, i.e., most toxicants act via more than one discrete pathway. We need to consider mechanisms to make sense of observed perturbations.^[@ref8]^

The term "Pathway of Toxicity" (PoT)^[@ref11]^ was coined for this purpose. PoTs are defined on a molecular level, i.e., with a high level of detail, which typically requires the generation of new experimental information. They aim for quantitative relations and fluxes. PoTs rely mostly on the untargeted identification of molecular interactions, typically by omics technologies. Mechanistic validation, i.e., establishing whether identified mechanisms are relevant for human or environmental health effects, has been suggested.^[@ref12]^

Pathway-oriented approaches are largely based on an assumed, principally linear sequence of events, i.e., A leads to B leads to C, and if we block B, A will not lead to C. Ultimately, however, there will be a need to combine linear pathways into network models.^[@ref13]^ This is the basic goal of Systems Toxicology: Computational network models,^[@ref14]^ e.g., virtual organ models,^[@ref15]^ based on our pathway knowledge make predictions about organs or whole organism responses (such as the virtual embryo palate closure model).^[@ref16]^ Comparison of model outputs with actual measurements will then show how close we are to understanding the characteristics of living networked systems.

Requirements for Test Systems to Derive Pathway Information {#sec3}
===========================================================

The pathway knowledge to build Systems Toxicology to a large extent still requires experimental models to derive such information, typically by omics technologies. The complexity of the organism, therefore, has to be reflected in the model. Test systems increasingly aim to reflect such aspects of the complexity of human physiology, for example, organotypic cultures or microphysiological systems. 3D organoid cultures^[@ref17]^ and their bioengineered environments move closer to this goal^[@ref18]^ by creating an organ-relevant model of multiple collaborating cell types, perfusion, organ architecture, and functionality. However, these elements are rarely combined in typical model systems.^[@ref19]^

The data generated by test systems need to be both reliable and relevant. The OECD^[@ref20]^ defines reliability in the context of formal validation as a measurement of "the extent to which a test method can be performed reproducibly within and between laboratories and over time, when performed by using the same protocol. It is assessed by calculating intra-laboratory and inter-laboratory reproducibility and intra-laboratory repeatability." While it is obvious that such reproducibility is necessary in experimental test systems, it is astonishing how seldom this requirement is actually addressed in either *in vivo* or *in vitro* test systems (except for a small number of formal validation studies). This situation has undoubtedly contributed to the current reproducibility crisis in science.^[@ref21]^ Recognizing this for *in vitro* testing, the Good Cell Culture Practice (GCCP) guidance^[@ref22]^ has recently been revamped^[@ref23]^ in an International GCCP collaboration.^[@ref24]^ The upgrade includes work toward *in vitro* reporting standards.^[@ref25]^ In short: 21st century toxicology starts with 21st century cell culture.^[@ref26]^ The European Union Reference Laboratory for alternatives to animal testing (EURL ECVAM) is currently coordinating the development of an OECD guidance document on Good *In Vitro* Method Practice (GIVIMP) which may be adopted in 2017.^[@ref27]^ GIVIMP should contribute to increased standardization and harmonization in the generation of *in vitro* information on test item safety.

What is measured must be not only *reproducible* but also *relevant*. Sometimes we reliably measure the wrong end point. The NIEHS (1997) definition of relevance indicates that it "describes whether a test method is meaningful and useful for a particular purpose. It is the extent to which the measurement result and uncertainty can accurately be interpreted as reflecting or predicting the biological effect of interest".^[@ref28]^ The way forward must focus our efforts on developing human cell-based *in vitro* systems,^[@ref29]^ and the challenge is that such systems need to permit the reliable measurement of end points of relevant functional biological processes.

Thus, reliability and relevance are the cornerstones of formal validation and should be a basis for the test systems used to deduce pathways and networks.^[@ref30],[@ref31]^ This assertion is not meant to suggest that only formally validated test systems should be used, only that it should be a goal. This is an iterative process, whereby the most mechanistically relevant test systems are used to further detail, challenge, and refine mechanistic understanding, which, in turn, can lead to improved test systems.

Requirements for Omics Data to Derive Pathway Information {#sec4}
=========================================================

Omics data can be a basis for the identification of pathways and networks,^[@ref32]^ but many challenges remain, especially for metabolomics,^[@ref33],[@ref34]^ which is important since it is closest to phenotypical changes.^[@ref35],[@ref36]^

The progress in omics technologies is impressive; new generations of instruments and chips offer real advantages and enable measurement of an enormous number of signals. Each omics technology has its own advantages and limitations,^[@ref37]^ as exemplified in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} for some of the more common technologies.

###### Advantages and Limitations of Common Omics Technologies

  technology                                                                                                         advantages                                                                                         limitations
  ------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------
  RNASeq (including RASLseq and TempO seq)                                                                           less costly and getting continuously cheaper                                                       number of transcripts (\>27,000 genes plus others)
  includes low abundance transcripts and noncoding RNA                                                               RNA changes do not imply protein changes                                                           
  fully quantitative                                                                                                 large data sets posing bioinformatics challenges                                                   
                                                                                                                     incomplete functional annotation                                                                   
  chip-based transcriptomics                                                                                         best standardized as to performance, reporting, and functional annotation                          number of transcripts (\>27,000 genes plus others)
  often strong signals (induction factors)                                                                           RNA changes do not imply protein changes                                                           
  interpretation by miRNA and transcription factor analysis advancing                                                semiquantitative at best                                                                           
  proteomics                                                                                                         sensitivity and specificity                                                                        large number of (modified) proteins (up to 1 million) require extensive method development and multiple measurements
  direct reflection of altered protein levels                                                                                                                                                                           
  may pick up direct compound--protein interactions                                                                                                                                                                     
  sensitivity of advanced mass-spectrometry-based methods gradually approaching that of chip-based transcriptomics   protein quantity changes do not imply functional changes                                           
  only very few laboratories able to implement advanced proteomics methods                                                                                                                                              
  less costly per measurement                                                                                        not all proteins in a sample can be identified and limited availability of antibodies              
  metabolomics                                                                                                       actual phenotypic change                                                                           metabolite identification by MS
  fewer number of substances (several thousands)                                                                     low sensitivity of NMR                                                                             
  less costly per measurement                                                                                        small effect strengths, i.e., often only slight changes over background activity                   
  NMR analysis is robust, noninvasive, and quantitative, and allows structural identification of metabolites         currently does not provide enough mechanistic information (this will improve in the near future)   
  MS analysis is sensitive, quantitative, and detects a high number of metabolites                                   little standardized as to performance, reporting, and functional annotation                        
  differences between platforms                                                                                                                                                                                         
  incomplete extraction of metabolites depending on extraction method                                                                                                                                                   

Because of limited throughput and high cost, only a few repeat measurements and experimental conditions can typically be tested. Combined with considerable variability of the measurements, this makes it difficult to separate statistically significant and meaningful changes from measurement artifacts, and small perturbations often escape detection. Cherry-picking individual significant signals and simple clustering on pathways often produces irrelevant results (as has been recently shown for metabolomics^[@ref34]^).

A promising approach is reduction in dimensionality of data, e.g., by transcription factor analysis^[@ref38],[@ref39]^ or miRNA network analysis of transcriptomics data. A further promising approach is multiomics data analysis (as pursued, for example, in the Human Toxome project),^[@ref40]^ whereby perturbations of the same pathways in several orthogonal omics technologies support greater confidence in reliability of pathway elucidation. One promising example of the result is proteogenomics, as well as the more challenging combination of transcriptomics with metabolomics.

It is often unclear whether the molecular changes and complex signatures detected by omics analyses actually represent adverse effects, and this lack of clarity hinders the broad application of omics measurements in safety assessments. To establish causal relationships, experimental challenges based on the Koch postulates or the Bradford-Hill criteria are necessary.^[@ref41]^

The same issue of relevance also applies to the use of omics for exposome measurements^[@ref42],[@ref43]^ involving the broad direct or indirect measurement of exogenous and endogenous substances in (human) biofluids as an indicator of the totality of exposure impacts. Thus, if we cannot interpret the patterns measured by omics, their use for exposome analysis is limited. Knowledge of mechanisms of toxicity could help identify meaningful signals.^[@ref44]^ This approach, giving rise to candidate pathways of toxicity, could be expanded with targeted measurements of components of the pathway as a basis for explaining signatures in exposome measurements.

Requirements for High-Throughput and High-Content Imaging Data to Derive Pathway Information {#sec5}
============================================================================================

The high-throughput screening (HTS) programs of ToxCast^[@ref45]^ and Tox21 measure numerous cellular responses, and understanding the pathways by which such cellular responses can lead to adverse outcomes is central in the interpretation and validation of the HTS data^[@ref46]^ and for designing future integrated testing strategies.^[@ref47]−[@ref49]^ Kleinstreuer et al. used computational clustering of ToxCast data from 641 environmental chemicals tested in primary human cell systems to identify potential chemical targets and mechanisms for elucidating toxicity pathways.^[@ref50]^

Similarly, high-content imaging (HCI) provides data allowing the analysis of pathways. Shah et al. used HCI to simultaneously measure multiple cellular phenotypic changes in HepG2 cells induced by 967 chemicals in order to identify the "tipping point" at which the cells failed to show recovery toward a normal phenotypic state.^[@ref51]^ The aim is to use such cellular tipping points to define points of departure for risk-based prioritization of environmental chemicals. These examples show that high-throughput and high-content imaging information can support pathway deductions, though experiences compared to omics approaches are rather limited.

Challenge of Linking Network Perturbations to Phenotypes {#sec6}
========================================================

Large-scale data streams can be used to develop an integrative qualitative and quantitative view of complex networks operative in cells and organs. Linking these networks to *in vivo* adversity, however, remains a challenge.

Liu and colleagues used a machine-learning approach that integrates chemical structure, bioactivity, and toxicity data to classify rodent hepatotoxicants.^[@ref52]^ While not directly aimed at elucidating pathways for liver toxicity, their data-driven approach empirically identifies putative biomarkers that could be key events involved in pathways to hepatic injury, inflammation, and neoplasia. Van den Hof et al. used gene expression profiles *in vitro* in HepG2 cells as a proof of principle for classifying known hepatotoxicants and nonhepatotoxicants.^[@ref53]^

In order to link exposure and effect, quantitative high-content imaging of cellular adaptive stress response pathways for chemical toxicity visualizing pathway activation serves as an example. Garcia-Serna et al. computationally combined chemical, structural, and biological hazard data of bioactive small molecules to gain a better understanding of the mechanisms leading to adverse effects.^[@ref54]^ Angrish et al. introduced a gas phase probe molecule into an *in vitro* system, observed normal steady state, added chemicals of interest, and quantitatively measured (from headspace gas) effects on metabolism that could be linked back to a well-defined corresponding *in vivo* effect.^[@ref55]^ Similarly, Gonzalez-Suarez et al. selected three well-known harmful and potentially harmful constituents in tobacco smoke, established a high-content screening in normal human bronchial epithelial cells using 13 indicators of cellular toxicity complemented with a microarray-based whole-transcriptome analysis followed by a computational approach leveraging mechanistic network models, to identify and quantify perturbed molecular pathways.^[@ref56]^

Challenge of Addressing Uncertainty in Computational Models for Systems Toxicology {#sec7}
==================================================================================

Computational models in Systems Toxicology can involve multiple biological scales, from molecular signaling to tissue dynamics to whole organisms, as well as time scales from fractions of a second to human lifetimes. Small uncertainties at one scale could cause large errors in predictions at another scale. In building reliable predictive computer model systems, it is therefore important to consider uncertainties,^[@ref57]^ including (at minimum): (1) Uncertainty in Systems Toxicology model structure: assessing whether the equations/network in use are appropriate. Would others fit the data equally well, but result in different predictions? (model selection). (2) Uncertainty in parameter values within the equations (minimization to fit data, inverse problems, parameter identifiability, dealing with variability): How sure are we that the numbers we are using in the simulation are accurate? Can we define probability distributions for them?. (3) Uncertainty propagation: how does the uncertainty in the model, parameters, and any inputs propagate through to uncertainty in our predictions of end points?

Assessing 1--3 is known as Uncertainty Quantification (UQ). UQ approaches are well developed, and often applied as standards in simple ADME compartmental concentration models, but extending UQ approaches to signaling pathway networks, adverse outcome pathways (AOP), and complex physiologically based pharmacokinetic (PBPK) models^[@ref58]^ requires more attention.

Challenge of Pathway-Based Testing Strategies {#sec8}
=============================================

Systems Toxicology can be seen as the ultimate goal of transitioning to a pathway-based approach in risk assessment, as it aims for the integration of our pathway knowledge into predictive models. This requires on the way, the generation of pathway-based information and the integrated use of such information to support risk assessment. By designing our testing strategies around the emerging pathway- and network-knowledge, we are converging with the Systems understanding and providing the data for its modeling.

Chemical risk assessment comprises hazard identification (adverse effects produced by a substance), hazard characterization (dose--response analysis of how much of a substance is required to produce adverse effects), and exposure assessment. Hazard characterization has traditionally used so-called "apical end points" (typically animal organ pathology) and has been plagued by interspecies and interindividual differences and the need for high-dose to low-dose and short-term to long-term extrapolations.^[@ref59]^ Additional uncertainty in exposure assessments arises due to multiple kinetic factors that can affect target concentrations. As a consequence, uncertainty factors are added in risk assessments to err on the "safe" side. Still, concerns remain: Are we looking for the right adverse effects? Are those observed effects relevant for humans? Do kinetics differ between animals and humans? Are vulnerable human subpopulations not addressed in animal studies? Could kinetics and biological barrier functions differ in disease or at certain life stages? Could coexposure to other toxicants (mixture effects) alter exposure and hazard thresholds?

Some of these questions have been addressed by the World Health Organization International Program on Chemical Safety (WHO/IPCS) Mode of Action (MOA) framework, which introduced the concept of a chain of causal key events leading to toxicity.^[@ref60]−[@ref62]^ Using this framework, the question of human relevance of animal data has been addressed for many well-characterized toxicants.^[@ref63],[@ref64]^

The MOA concept was subsequently adapted by the OECD Adverse Outcome Pathway (AOP) framework,^[@ref65]−[@ref67]^ which aims to identify key events in toxicity pathways between a molecular initiating event (MIE) and an adverse outcome (AO). In contrast to MOAs, AOPs are chemical-agnostic, i.e., they attempt to describe common key events triggered by multiple chemicals. Building a knowledgebase of these key events will assist in establishing the relevance of test systems.

It is important to note that AOPs are designed to be parsimonious descriptions that can be used for regulatory purposes, rather than detailed mechanistic descriptions of systems toxicity networks. The aim is to identify as many key events as necessary but as few as possible.^[@ref68]^ The different levels of detail between AOPs and PoTs has led to the existence of different repositories, i.e., the AOP-Wiki^[@ref69]^ and Effectopedia^[@ref70]^ for AOPs, versus the Human Toxome Knowledgebase under construction.

In 2013, the Scientific Committees of the European Commission Directorate General for Health and Consumer Safety issued an opinion^[@ref71]^ that "There is a trend/need to change the basis of risk assessment from the one based on standard tests to one that is centered on modes of action. In investigations using laboratory animals, increasing importance should be directed to characterizing the mode of action with less emphasis to end points based on histopathological criteria, body and organ weight, and blood chemistry." This approach was adopted in the EU research program SEURAT-1 (Safety Evaluation Ultimately Replacing Animal Testing), funded by the European Community's Seventh Framework Programme FP7,^[@ref72]^ and subsequently in EUToxRisk,^[@ref73],[@ref74]^ a large-scale, six-year EU project aiming to integrate *in vitro* and *in silico* toxicology, read-across methods, and adverse outcome pathways for the prediction of repeated dose systemic toxicity (liver, kidney, lung, and nervous system) and developmental/reproductive toxicity. It focuses on regulatory hazard and risk assessment rather than on individual test methods. AOPs and integrated approaches to testing and assessment (IATA) play a central role in the EU-ToxRisk project. The goal is to develop quantitative AOPs (qAOPs) for regulatory assessment of chemical safety in humans.^[@ref73]^ This is all part of a systematic development of safety sciences.^[@ref75]^

Many pieces of the puzzle are emerging from various places, e.g., Allen and colleagues^[@ref76]^ proposed a unified approach to defining MIEs for risk assessment based on QSARs and receptor activation. Once chemicals can be accurately mapped to MIEs, potential AOPs can be inferred. This approach was implemented by Mellor and colleagues^[@ref77]^ by computationally identifying structural alerts for nuclear receptor (NR) activators from 12,713 NR agonists in ChEMBL, a manually curated chemical database of bioactive molecules with drug-like properties by the European Bioinformatics Institute (EBI), of the European Molecular Biology Laboratory (EMBL). These structural alerts can be used to prioritize chemicals by NR-mediated pathways to hepatic steatosis. Similarly, Mekenyan and colleagues^[@ref78]^ computationally linked chemicals to MIEs involved in respiratory sensitization based on absorption into epithelial membranes (physicochemical rules) and electrophilic reactivity (simulating metabolism). They further evaluated the predictive accuracy of their approach using known respiratory sensitizers. Similarly, Roberts and Aptula^[@ref79]^ studied electrophilic reactivity in the context of skin sensitization potency.

Vinken^[@ref80]^ provides an overview of constructing AOPs involved in drug-induced liver injury (DILI) with AOs steatosis, cholestasis, and fibrosis. Potential applications of such AOPs include read-across or chemical grouping based on MIEs using cheminformatics, as well as integrated approaches to testing and assessment (IATA).

From a regulatory point of view, IATAs are essential for consistent and transparent evaluation of the relevance of AOP-based (frequently *in vitro*) data for specific end points and regulatory decisions.^[@ref81]−[@ref83]^ The first example of AOP-based IATA development is for *in vitro* skin sensitization testing.^[@ref82]^ Two *in vitro* test guidelines have been adopted by the OECD, covering the molecular initiating event of the AOP for skin sensitization (covalent protein binding; OECD Test Guideline 442C)^[@ref84]^ and the second key event (keratinocyte inflammation; OECD Test Guideline 442D).^[@ref85]^ Combining the results of these two assays is more predictive than each assay alone,^[@ref86]^ leading to an industry proposal for an Integrated Testing Strategy^[@ref87]^ based on readouts from multiple key events, and an associated decision support system for the risk assessor. On the regulatory side, the U.S. Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) is developing integrated decision strategies based on *in vitro*, *in chemico*, and *in silico* information derived from the skin sensitization AOP.^[@ref88]^ It is clear that much work needs to be done to provide simple, acceptable AOP-based IATAs for regulators.^[@ref89]^

Outstanding regulatory challenges^[@ref90],[@ref91]^ include the need for reliable data and data analysis, in addition to quantifying uncertainty due to genetic background, cell type and topography, life-stage, and exposure temporality in dose--response modeling.

Altogether, the AOP and PoT work is establishing the pathway-based approach to safety testing, which forms the basis of the adaption of Systems Toxicology at a later stage.

Emerging Building Blocks and Their Applications for Systems Toxicology {#sec9}
======================================================================

Mechanistic toxicology is flourishing in academic research and increasingly impacting additional or alternative evidence on the regulatory process. A lot of this is contributing to the development of Systems Toxicology. A few examples drawn from the congress and a recent virtual issue of this journal and *Environmental Sciences and Technologies*([@ref92]) are used to illustrate ongoing progress in the following.

Physiologically Based Pharmacokinetic (PBPK) Modeling {#sec9.1}
-----------------------------------------------------

Computational PBPK models are used to estimate xenobiotic concentrations in various organs.^[@ref93]^ Detailed permeability-limited PBPK models of the liver, kidney, lung, brain, intestine, and skin have been described.^[@ref94]−[@ref99]^ Both chemical properties and modeled physiology can be altered to investigate the effects of a given xenobiotic in individuals of different ethnicities, ages (e.g., pediatric and geriatric), or altered levels of organ function (e.g., renal and hepatic impairment).^[@ref100]^ The combination of PBPK modeling with *in vitro--in vivo* extrapolation (IVIVE) permits bottom-up prediction of absorption, clearance, and distribution of xenobiotics.^[@ref101],[@ref102]^

The combination of PBPK with pharmacodynamic or toxicodynamic models enables investigation of safety risks under conditions which are not amenable to clinical investigation.^[@ref103],[@ref104]^ For example, using permeability-limited PBPK models, it was possible to predict the impact of a transporter genotype on the pharmacodynamics of rosuvastatin within the liver.^[@ref105]^ PBPK models have also been coupled with information about the effects of xenobiotics on heart tissue (ion current disruption, contractility modification, and metabolic pathways disturbance leading to cell apoptosis) to simulate the cardiotoxicity of various agents. The verification of the simulation results against clinically observed end points (i.e., QT prolongation) demonstrates the usefulness of such combined modeling in drug safety assessment.^[@ref106]^ Also, the risk of human nephrotoxicity can be estimated from animal studies by modeling drug-specific transporters to derive local kidney concentrations.^[@ref107]^

Hepatic Toxicity {#sec9.2}
----------------

One example of network modeling is a large scale mechanistic simulation combining Flux Balance Analysis of Genome Scale Metabolic Network of human hepatocyte with a large-scale model of nuclear receptor signaling.^[@ref108]^ This model can qualitatively link gene activity perturbation with bile acid homeostasis, thus permitting mechanistic assessment of the role of genetic polymorphism in toxicity and interpretation of omics data.

Cardiac Toxicity {#sec9.3}
----------------

Blockade of the hERG potassium channel by direct binding of a drug molecule causes QT prolongation and increases pro-arrhythmic risk. Since 2005, candidate drug compounds must be screened for hERG binding (ICH S7B guideline)^[@ref109]^ and clinical long QT (ICH E14 guideline).^[@ref110]^ These guidelines have been remarkably successful in preventing compounds with increased pro-arrhythmic risk reaching the market; this is a highly sensitive approach (few false negatives), but many safe compounds on the market since well before 2005 would fail to meet these guidelines, suggesting that they may have low specificity (many false positives). It has been proposed that multiple ion channel block may explain the discrepancy in sensitivity and specificity;^[@ref111]−[@ref113]^ put simply, blocking additional ion channels may compensate for blocking of hERG and reduce pro-arrhythmic risk.

In addition to multichannel effects, it is also important to consider drug kinetics at particular ion channels. Does the drug simply bind to the channel and block its current, or do we need to consider which conformational states the drug can bind, and how the channel behavior is affected by this?^[@ref114]−[@ref116]^

The development of improved test systems and bioanalytical methods has enabled a systems approach for measuring drug binding effects and simulating their consequences.^[@ref117]^ First, new cell-line technologies (overexpression of ion channels of interest in immortal cell lines, together with automated patch-clamp ion current screening platforms) have made it possible to routinely screen compounds for blockade of multiple cardiac ion channels.^[@ref118]^ Second, mathematical models of cardiac electrophysiology are very well established; they integrate the information on multiple ion channel effects by describing how action potentials are formed from a set of voltage-dependent ionic currents.^[@ref119]^ Predicted and measured drug-induced action potential changes can be used as risk indicators. Notably, interference with one ion channel alters membrane voltage and thus the sensitivity to block of other ion channels. Modeling involves not just the biochemistry of ion channels and gene/protein networks but also the biophysics of membrane electrophysiology. These mathematical models are now in routine use to predict the results of safety tests^[@ref120],[@ref121]^ and are an integral element of new initiatives to replace existing guidelines with more accurate preclinical assessments of pro-arrhythmic risk than the existing clinical studies.^[@ref122],[@ref123]^

Renal Toxicity {#sec9.4}
--------------

In recent years, the toxicological community has shifted focus from animal studies to an *in vitro* molecular understanding of chemical-induced biological perturbations.^[@ref124]^ The ability to map pathway activation at the mRNA level has uncovered networks of toxicologically relevant processes, including stress response pathways,^[@ref125]^ that are involved at the early stages of many chemical-induced pathologies.^[@ref126],[@ref127]^ Integrating transcriptomics with other omics information (such as proteomics and metabolomics) dramatically increases the depth of biological interpretation, allowing us to establish where breaks in cellular homeostatic regulation occur. We should be careful, however, to confirm the relevance of this information in real world situations and to normal human biology. Where possible, it is best practice to use human, stable, noncancerous, differentiated cells, rather than unstable, highly proliferating, glycolytic cells with practically alien karyotypes (such as A549 cells or MCF7 cells).^[@ref128]^ It is also important to include adequate exposure data when interpreting high content toxicological data.

In the EU seventh Framework Project, Predict-IV, integrated omics analyses were combined with intracellular dosimetry in *in vitro* liver, kidney, and CNS test systems. Intracellular dosimetry analyses using inductively coupled plasma mass spectrometry (ICP-MS) and omics data (transcriptomics, metabolomics, and proteomics) were captured during the administration of renal toxicants for up to 14 days^[@ref129]−[@ref131]^ in the *in vitro* human proximal tubule RPTEC/TERT1 cell line, which has a close-to-normal cellular phenotype^[@ref132]−[@ref134]^ and can be maintained as a tissue monolayer for months.^[@ref132],[@ref135]^ Cyclosporine A (CsA), an immunosuppressant agent and suspected nephrotoxin, is highly lipophilic and thus not readily soluble in aqueous solutions such as cell culture medium. At 15 but not 5 μM, CsA massively accumulated in the cells, likely due to the saturation of the ABC extrusion transporters. Integrated analysis of the exposure and omics data indicated that CsA at 15 μM floods the lipophilic compartments of the cell and causes both ER and mitochondrial disruption; the cells manage to stay alive by Nrf2 and ATF4 activation and by switching back to glycolysis for energy requirements. Increased glycolysis is reflected in increased lactate in the supernatant medium, which can thus be used as a surrogate marker for toxicity.^[@ref136]^ The therapeutic mode of action of CsA is binding to cyclophilin and subsequent reduction of T cell activation and their immune response. In the RPTEC/TERT1 cells, CsA induced apical excretion of cyclophilin B (CyP-B) as a surrogate marker of clinical efficacy at both 5 and 15 μM.

From the lactate and CyP-B data, an *in vitro* therapeutic window is apparent for CsA, whereby strong CyP-B induction starts at 3 μM, but enhanced glycolysis does not begin until ≥10 μM ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). Human kinetic data indicate that CsA at therapeutic doses will not reach 10 μM in plasma, demonstrating a narrow therapeutic window between efficacy and toxicity.

![Effects of 24 h treatment with cyclosporine A (CsA) in RPTEC/TERT1 human kidney cells. Concentrations of cyclophilin B (CyP-B) and lactate in the supernatant medium were used as measures of efficacy and toxicity, respectively.^[@ref131]^](tx-2017-00003u_0001){#fig1}

It is understandable that there is some skepticism in accepting safety data derived solely *in vitro*, and thus, it is necessary to increase confidence by comparison with similar *in vivo* data where available. Because of species differences, comparing *in vitro* human cell data with *in vivo* animal data is unsatisfactory. A way around this is to verify *in vitro* biomarkers in clinical samples from diseased patients, which often have similar underlying etiology. We have shown, for example, that IL-19 is induced and secreted into the supernatant medium in RPTEC/TERT1 kidney cells exposed to several nephrotoxins, including zoledronate and antiviral compounds.^[@ref137]^ IL-19 was found elevated in the urine of CKD patients and exhibited a negative correlation to the estimated glomerular filtration rate (a measure of renal function) and a positive correlation to urinary *N*-acetyl-beta-[d]{.smallcaps}-glucosaminidase and lipocalin 2 (biomarkers of proximal tubule injury). This type of *in vitro* to *in vivo* correlation increases the confidence in the relevance of specific biomarkers and their pathways.^[@ref138]^

Conclusions {#sec10}
===========

Three developments are enabling the progress of the Systems Toxicology approach: (1) reliable and relevant *in vitro* test systems, (2) high-throughput and high-content methods generating large-scale data streams, and (3) *in silico* model systems. All require delineation of pathways of toxicity. Development of pathway-based approaches in toxicology will require a mountain of work. The state-of-the-art approach summarized here is like a snapshot taken from the foothills. No single picture of a mountain can capture its complexity, but we believe that the current perspective will help us further plan the route to the top.
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